[Concomitant treatment of the osteoporotic drugs].
Osteoporotic drugs are classified to 3 categories ; anti-resorptives, supplemental and anabolic drugs. A lot of evidence has been made about each osteoporotic drug. Although concomitant drug subscriptions are often used by many physicians, little evidence has been ever made about the concomitant drug treatment. Theoretically different categorized drugs should be combined in concomitant treatment. Fragility fracture risks have been tested compared alendronate (Aln) mono-therapy and Aln + alfacalcidol (VD(3)) for 2 year in JOINT02 of ATOP study. Aln + alfacalcidol (VD(3)) concomitant treatment has significantly reduced vertebral fracture risk compared with Aln mono-therapy in patients with advanced osteoporosis with multiple and high SQ grade vertebral fracture and also reduced weight bearing bone fracture risk.
Bone and Joint Surgery, Seirei Hamamatsu General Hospital, Japan.
Satoshi
S
Mori
D019386:Alendronate / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D014807:Vitamin D / Q000627:therapeutic use; D014812:Vitamin K / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D014812:Vitamin K; D014807:Vitamin D; D019386:Alendronate